Our CEO authored the original, definitive drug evaluation review on Gaucher's disease, which led to FDA approval based on a trial in 11 patients, demonstrating our ability to effectively communicate complex clinical data and support regulatory processes.
Writing a comprehensive book on myelodysplastic syndromes (MDS) for clinicians, providing valuable insights and guidance for healthcare professionals treating this rare blood disorder.
Conducting a systematic literature review on the burden of illness for haemophilia, shedding light on the impact of this rare bleeding disorder on patients and healthcare systems.
Completing literature reviews for biomarkers in rare diseases, contributing to the ongoing efforts to identify novel diagnostic and therapeutic targets for these conditions.
Publishing on persistence and adherence for treatment for familial hypercholesterolemia and primary lipidemias, highlighting the importance of effective patient management strategies in these rare conditions.
Developing a slide set on the value of therapy for atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH), ensuring healthcare professionals are well-informed about these rare blood disorders and their treatment options.
*Not their real name
Due to the sensitive nature of most of our work we are sometimes required to anonymise these public facing testimonials, however we can provide details, including references and case studies later in the process.
Their collective dedication to excellence, unwavering commitment to ethical standards, and passion for delivering exceptional results are the driving forces behind our agency's continued success in the ever-evolving world of medical communications.